ClinicalTrialsFinder
RecruitingPhase 2NCT07073638

Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of RESP30TB in Tuberculosis

A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults With Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis

Sponsor

Thirty Respiratory Limited

Enrollment

24 participants

Start Date

Oct 13, 2025

Study Type

INTERVENTIONAL

Conditions

Pulmonary Tuberculoses

Summary

A Phase 2 Trial to Evaluate the Safety and Tolerability and Early Bactericidal Activity of Nebulised RESP30TB in Adults with Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria7

  • Provide written, informed consent prior to all trial-related procedures and agree to undergo all trial procedures.
  • Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
  • Newly diagnosed pulmonary TB.
  • Rifampicin susceptible pulmonary TB as determined by molecular testing.
  • Ability to produce an adequate volume of sputum as estimated from a pre-treatment overnight sputum collection sample (estimated 10 mL or more).
  • Spirometry performed during screening with a Forced Expiration Volume in the first second (FEV1) of ≥ 40%.
  • Be of non-childbearing potential or willing to use effective methods of contraception, as defined in section 4.3.4.

Exclusion Criteria8

  • HIV positive AND CD4 < 350 cells/mm3 OR are receiving antiviral therapy (ART)
  • Baseline Methaemoglobin saturation (SpMet) >3%.
  • Female patients who is pregnant or breast-feeding.
  • Patients planning to conceive a child within the anticipated period of trial participation and for at least 90 days after the last dose of IMP in the trial.
  • Participation in other clinical studies with investigational agents within 8 weeks prior to screening.
  • Treatment received for this episode of TB with any drug active against M.tb
  • Treatment with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening.
  • Treatment with NO and other NO donor agents, phosphodiesterase inhibitors and lung surfactant drugs, within 30 days prior to screening.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRESP30TB

Nitric Oxide agent

DRUGHRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)

isoniazid 75 mg (H), rifampicin 150 mg (R), pyrazinamide 400 mg (Z), ethambutol 275 mg (E)

Locations(1)

TASK Clinical Research Centre

Cape Town, Bellville, South Africa

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07073638